Form 8-K Verrica Pharmaceuticals For: May 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Verrica Pharmaceuticals (VRCA) PT Raised to $12 at Jefferies
May 14, 2024 9:35 AM EDTJefferies analyst Glen Santangelo raised the price target on Verrica Pharmaceuticals (NASDAQ: VRCA) to $12.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "Updating model to reflect 1Q results. Overall, we remain encouraged with the launch and continue to see opportunity for... More
